SCHEMBL22206151

SCHEMBL22206151

CN1CCN(Cc2cc(Cl)nc(-c3cccc([N+](=O)[O-])c3)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
MAPT P10636 5/20 0.49
STAT1 P42224 1/20 0.49
MAPK1 P28482 6/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
KDM4E B2RXH2 3/20 0.47
LMNA P02545 2/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 3/20 0.47
NPSR1 Q6W5P4 2/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
RECQL P46063 1/20 0.43
MET P08581 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29838416 1.00 ALDH1A1 (0.49) ALDH1A1MAPTSTAT1MAPK1SMN1; SMN2
SCHEMBL29838339 0.87 ALDH1A1 (0.53) ALDH1A1MAPTMAPK1SMN1; SMN2KDM4E
SCHEMBL22206146 0.87 ALDH1A1 (0.53) ALDH1A1MAPTMAPK1SMN1; SMN2KDM4E
SCHEMBL22206162 0.82 ALDH1A1 (0.44) ALDH1A1MAPTMAPK1SMN1; SMN2KDM4E
SCHEMBL2716970 0.78 ALDH1A1 (0.73) ALDH1A1MAPTMAPK1SMN1; SMN2KDM4E
SCHEMBL22206168 0.76 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2LMNATDP1
SCHEMBL29838492 0.76 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2LMNATDP1
SCHEMBL22206142 0.76 ALDH1A1 (0.54) ALDH1A1MAPTSMN1; SMN2KDM4ELMNA
SCHEMBL29743070 0.76 ALDH1A1 (0.54) ALDH1A1MAPTSMN1; SMN2KDM4ELMNA
Hydrochloric Acid SCHEMBL9871479 0.74 ALDH1A1 (0.49) ALDH1A1MAPTSTAT1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111212833-B Phenylpyridine derivatives and pharmaceutical compositions containing the same 株式会社大熊制药 2022-09-06 CN disclosed
EP-3696176-B1 NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DAE WOONG PHARMA (KR) 2022-05-04 EP disclosed
US-11149019-B2 Phenylpyridine derivative and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-10-19 US disclosed
US-11149019-B2 Phenylpyridine derivative and pharmaceutical composition comprising the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2021-10-19 US disclosed
EP-3696176-A1 NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Daewoong Pharmaceutical Co., Ltd. (KR) 2020-08-19 EP disclosed
US-20200223821-A1 Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-16 US disclosed
US-20200223821-A1 Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2020-07-16 US disclosed
CN-111212833-A Novel phenylpyridine derivative and pharmaceutical composition comprising same 株式会社大熊制药 2020-05-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200223821-A1 Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same PDCD1, PDCD5, PDCD11 ALDH1A1 239/4885MAPT 1659/4885STAT1 3030/4885
US-11149019-B2 Phenylpyridine derivative and pharmaceutical composition comprising the same DPYD, PDCD5, PDCD1 ALDH1A1 153/4885MAPT 1895/4885STAT1 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.